Clinical trials
Relapsed or Refractory Hematologic Malignancies clinical trials
Below are recruiting relapsed or refractory hematologic malignancies clinical trials, each written for real people, not researchers. We’re tracking 1,347 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT04480853RecruitingPhase 4
Fingolimod start study for adults with relapsing MS
This study checks how safe and effective fingolimod is when adults with relapsing-remitting multiple sclerosis start it for the first time. It may help confirm whether this treatment works well and is tolerated in newly treated patients.
Kaohsiung CityAges 20–100 - NCT04501120RecruitingPhase 1/Phase 2
Study drug for relapsed AML and related blood cancers
This early-phase trial tests lisaftoclax, alone or with other medicines, in people whose acute leukemia has returned or did not respond to prior treatment. It aims to find out how well the treatment works and how safe it is, especially for patients who may not be able to take standard chemotherapy.
Beijing, Beijing MunicipalityAges 18 years+ - NCT04511013RecruitingPhase 2
Trial for BRAF-mutant melanoma spread to the brain
This Phase 2 study tests whether a 3-drug plan (encorafenib + binimetinib + nivolumab) works better than ipilimumab + nivolumab for melanoma that has spread to the brain. If you qualify, you’ll get either treatment and have frequent brain scans to track how well it controls the tumors.
Birmingham, AlabamaAges 18 years+ - NCT04518475RecruitingPhase 4
Eltrombopag with rituximab versus eltrombopag alone for ITP
This trial compares two treatment approaches for adults with primary immune thrombocytopenia (ITP), a condition where platelet counts are too low. It looks at whether adding rituximab to eltrombopag helps control ITP better and more safely.
TianjinAges 18–60 - NCT04546399RecruitingPhase 2
Blinatumomab with or without nivolumab for first relapse ALL
This study compares blinatumomab alone versus blinatumomab plus nivolumab in young people whose B-cell ALL has returned for the first time. It aims to see whether adding nivolumab improves control of the leukemia after relapse.
Birmingham, AlabamaAges 1–30 - NCT04587856Recruiting
Study why blood cancer returns after donor stem cell transplant
This study looks at why a bone marrow disorder (MDS) can come back after a donor stem cell transplant. It may help researchers understand relapse, which could improve future care for people getting transplants.
BariAges 18 years+ - NCT04604041Recruiting
Study early warning signs in relapsing-remitting multiple sclerosis
This study looks at “subclinical markers,” meaning early or hidden body changes that may show how relapsing-remitting multiple sclerosis (MS) is doing even when symptoms seem mild. It may help researchers find better ways to monitor MS and detect changes sooner.
SplitAges 18–65 - NCT04625907RecruitingPhase 1/Phase 2
Study testing treatment options for children and adults with RMS
This study tests different treatment approaches for rhabdomyosarcoma (RMS) in children and adults, including newly diagnosed high-risk cases, people needing radiotherapy, and people whose RMS has returned. It’s designed to find safer dosing and more effective therapy while checking whether participants can proceed based on health and timing requirements.
BrisbaneAges Any age - NCT04644016RecruitingPhase 2
Cord blood transplant for children and young adults with blood cancers
This Phase 2 trial studies using a cord blood transplant after finding it is risky enough that standard treatment may not be sufficient. It may help certain children and young adults with specific leukemia, lymphoma, and some non-cancer blood/immune or inherited disorders who do not have a well-matched donor available in time.
New York, New YorkAges Up to 21 years - NCT04678401RecruitingPhase 1
Trial tests transplant using a half-matched donor for high-risk leukemia
This Phase 1 trial tests a special bone marrow transplant using a related “half-matched” donor (haploidentical), without a specific immune-suppressing medicine (“IS-free”). It’s for adults with certain high-risk AML or MDS to see if this approach can improve control of the disease while tracking safety.
Boston, MassachusettsAges 18–75 - NCT04758000RecruitingPhase 2
Metformin after bone cancer treatment to prevent relapse
This Phase 2 study tests whether taking metformin after surgery and chemotherapy can reduce the risk of bone cancer coming back in people at high risk of relapse. You may be eligible if you have osteosarcoma or Ewing sarcoma that is not currently spread and you meet specific lab and health criteria.
BolognaAges 14 years+ - NCT04776330RecruitingPhase 1/Phase 2
BCMA-targeted CAR-T for relapsed or refractory multiple myeloma
This trial tests a lab-made immune cell therapy (CAR-T) designed to attack a protein called BCMA on myeloma cells. It’s for adults whose multiple myeloma or related plasma cell disease has come back or didn’t respond to prior treatment, aiming to improve cancer control.
Kunming, YunnanAges 18–75 - NCT04794777RecruitingPhase 3
Tests targeted scans and rescue radiation for returning prostate cancer
This trial studies whether a targeted scan (PSMA PET/CT) can help doctors choose the best “salvage” radiation treatment when prostate cancer comes back by PSA blood tests after surgery. It may help some people avoid under- or over-treating the areas where the cancer is returning.
Gothenburg, GöteborgAges 18 years+ - NCT04834024RecruitingPhase 3
MIL62 plus lenalidomide vs lenalidomide alone for rituximab-refractory lymphoma
This trial tests whether adding MIL62 to lenalidomide works better than lenalidomide alone in people with follicular lymphoma that no longer responds to rituximab. The goal is to improve tumor control by using an additional medicine along with standard treatment.
BeijingAges 18 years+ - NCT04838041RecruitingPhase 2
Testing stopping treatment after asciminib for CML relapse
This trial looks at whether people with chronic-phase CML who tried stopping a prior CML medicine and had to restart can later stop treatment again after a set period using asciminib. It checks whether you can stay in a deep remission (“free remission” without the usual CML tablets).
Detroit, MichiganAges 18 years+ - NCT04855695RecruitingPhase 1/Phase 2
Study for relapsed mantle cell lymphoma using targeted oral drugs
This Phase 1/2 study tests a combination of oral and antibody treatments for mantle cell lymphoma that has come back (relapsed) or did not respond (refractory). It aims to control the cancer and uses blood/tumor test results to guide some treatment timing for eligible participants.
Chicago, IllinoisAges 18 years+ - NCT04897321RecruitingPhase 1
CAR T therapy for children with B7-H3 solid tumors
This early-phase study tests a lab-made immune therapy (CAR T cells) made from your own cells to treat children’s solid tumors that have a specific marker called B7-H3. It is designed for kids whose cancer has come back or did not respond to standard treatment, aiming to shrink tumors and keep the therapy safe.
Memphis, TennesseeAges Up to 21 years - NCT04914026Recruiting
MicroRNA test for testicular cancer diagnosis
This study looks at tiny genetic signals called microRNAs to see if they can help identify or track testicular cancer. It may help doctors recognize testicular cancer more accurately and decide what to do next.
BergenAges 18–70 - NCT04924868RecruitingPhase 3
Ursodeoxycholic acid to prevent gallstone pancreatitis returning
This trial tests whether ursodeoxycholic acid (a bile medicine) can help prevent complications from gallstone-related acute pancreatitis from coming back after you leave the hospital. It may help reduce repeat problems linked to gallstones, especially after an initial pancreatitis episode.
Santiago de Compostela, A coruñaAges 18 years+ - NCT04928677RecruitingPhase 1
Codrituzumab for children and young adults with GPC3-positive solid tumors
This Phase 1 study tests codrituzumab, an antibody medicine, in children and young adults whose solid tumor has come back or did not respond to standard treatment. It’s designed to see how the treatment works and how safe it is, especially for tumors that test positive for GPC3.
Los Angeles, CaliforniaAges 1–21 - NCT07003295RecruitingPhase 2
Glofitamab for mantle cell lymphoma that returned after CAR-T
This trial tests a new drug, glofitamab, for mantle cell lymphoma that came back or didn’t respond after CAR-T cell therapy. It aims to see if glofitamab can shrink or control the lymphoma.
Duarte, CaliforniaAges 18 years+ - NCT07302347RecruitingPhase 1/Phase 2
Study of pembrolizumab for different cancers in Japan
This trial tests a drug called pembrolizumab (Keytruda) to see if it helps people with several types of cancer, including relapsed or refractory lymphoma, melanoma, MSI-high or TMB-high solid tumors, and Merkel cell carcinoma. The goal is to understand if this immunotherapy can shrink or control the cancer.
Nagoya, Aichi-kenAges 6 months+ - NCT04972760RecruitingPhase 3
Baricitinib for active dermatomyositis in adults
This trial studies whether baricitinib can improve symptoms and test results in adults with active dermatomyositis (a muscle and skin inflammation disease). It’s for people whose disease is still active despite prior treatment or who have been recently diagnosed.
ParisAges 18–64 - NCT04981119Recruiting
Test apheresis for CAR T manufacturing in HLA-A2 solid tumors
This trial studies how a process called apheresis is used to make CAR T cells for people with certain solid tumors. It is designed for tumors that have lost a specific immune marker (HLA-A*02), which may affect how well CAR T therapies work.
Gilbert, ArizonaAges 18 years+
Hear when a new Relapsed or Refractory Hematologic Malignancies trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for relapsed or refractory hematologic malignancies?
- Yes. Clin2 currently lists 1,347 recruiting relapsed or refractory hematologic malignancies studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a relapsed or refractory hematologic malignancies trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a relapsed or refractory hematologic malignancies trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Relapsed/Refractory B-cell Malignancies
- Relapsed/Refractory Hematological Malignancies
- Relapsed/Refractory Multiple Myeloma
- Relapsed/Refractory Acute Myeloid Leukemia
- Relapsed or Refractory Multiple Myeloma
- Relapsed or Refractory Multiple Myeloma (RRMM)
- Relapsed/Refractory B-cell Lymphoma
- Non-Hodgkin Lymphoma Refractory/ Relapsed
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.